Popular Posts

Thursday, 23 November 2017

KBR, Socar JV bags FEED contract for Absheron gas field




KBR Inc said that its SOCAR-KBR Limited Liability Company (SKLLC) joint venture has been awarded a front-end engineering design (feed) contract for the topsides of the Absheron Early Production Project.
The platform will be located at Socar's oil rocks facility and will deliver gas and condensate into the Socar network.
This award marks the 3rd award to the SKLLC joint venture since its inception in mid-2015. SKLLC was formed to help further Azerbaijan's ambition for creating a world-class Azerbaijan based engineering company.
Socar and Total signed a framework agreement in late 2016 on the main contractual and commercial principles regulating the program for the first phase of development of the Absheron field.
At the first stage, the field development includes drilling one well at a depth of 450 meters. The extraction will amount to 1.5 billion cubic meters of gas a year, which will fully flow to the domestic market of Azerbaijan, as well as significant amounts of condensate. First gas could be produced in 2019.

BP to sell North Sea assets to Serica for £300 million




BP PLC has agreed to sell a package of its interests in the Bruce assets in the North Sea to Serica Energy plc.
BP currently operates the assets, which comprise the Bruce, Keith and Rhum fields, three bridge-linked platforms and associated subsea infrastructure.
Overall, BP expects to receive payments of around £300 million, the majority of which will be received over the next four years.
BP aims to complete the sale and transfer of operatorship in the 3rd quarter of 2018.
The Bruce field was discovered in 1974 and came into production in 1993, with Keith tied back to Bruce in 2000. Rhum, a high-pressure, high-temperature satellite field located 40 kilometres to the north of Bruce, was brought into production in 2005
The Bruce assets are expected to transition to Serica as a fully operational entity with around 110 staff who operate and support the assets expected to transfer with the business.

Arlanxeo rubber used in World Cup 2018 soccer ball




Arlanxeo said that its bio-based EPDM rubber is used in the Adidas soccer ball of the World Cup 2018.
The EPDM rubber (ethylene-propylene-diene monomer) Keltan Eco 6950 is the rubber basis for a sponge rubber layer directly underneath the “Telstar 18” ball’s outer cover. It serves as a moldable cushion for the ball and supports optimal bounce characteristics during games.
Materials that are used in this layer must meet strict requirements in properties such as density, hardness and weight, and they must also demonstrate good processability. The most important performance characteristic, however, is the elasticity and resilience of the layer.
Keltan Eco is the world’s first EPDM rubber manufactured using bio-based ethylene extracted from sugarcane. Depending on the ethylene content of each rubber grade, the proportion of bio-based material ranges between 50 and 70 percent.
Keltan Eco 6950 – the type used by Adidas – is characterized by its amorphous structure and high crosslinking density. This leads to good low-temperature properties and meets the requirements for the best possible elasticity and resilience.
With six different grades of Keltan Eco rubber currently on the market, Arlanxeo is supporting the move towards more sustainable products and matching the ever-stricter environmental requirements to help reduce its carbon footprint, whether in the sporting goods industry or the automotive industry.

Biologics segment dominates the market




Market Snapshot
In pharmaceutical continuous manufacturing technology, active ingredients are produced in compact, closed units, leveraging automation. Hence, it requires fewer manual interventions. Production steps carried out sequentially in a classic batch process are combined in a continuous process. All these help to bring about continued utilization of production capacity. This, in turn, serves to reduce fluctuations in production, improve yields, and lower costs of operation and equipment. On account of such advantages, the method is seeing fast adoption, according to a report by Transparency Market Research. 
Other advantages of pharmaceutical continuous manufacturing technology are the superior development speeds, higher process safety when employing hazardous chemistries, and the opportunity to perform reactions that cannot be run under batch processing. 
A study by Transparency Market Research forecasts the global pharmaceutical continuous manufacturing technology market to expand at a healthy CAGR of 8.8 percent from 2017 to 2025. Expanding at this pace, the market which was worth $1.74 bn in 2016 is expected to attain a value of $3.693 bn in 2025.
Contract Manufacturing Organizations in Asia Pacific to Drive Market
Some of the key application segments of the global pharmaceutical continuous manufacturing technology market are biologics, dry powders, active pharmaceutical ingredients etc. Of them, the segment of biologics accounts for a dominant position in the market. It held a share of about 35.3 percent in the global market in 2016. It was trailed by active pharmaceutical ingredient.
Application-wise, the global pharmaceutical continuous manufacturing technology market can be divided into contract manufacturing organizations, pharmaceutical companies etc. Currently, pharmaceutical companies lead the market with maximum demand and are trailed by contract manufacturing organizations. In the near future, the contract manufacturing organizations in Asia Pacific region are predicted to fuel market growth majorly. Along with increasing awareness about the technology, various initiatives by FDA are also egging manufacturers to shift to continuous manufacturing over batch manufacturing process.

Sumitomo acquires 83 pc stake in BRA Group




Sumitomo Chemical Co Ltd has acquired 82.9 percent of shares in Botanical Resources Australia Pty Ltd and its affiliated companies (the BRA Group) from the shareholders, and made the BRA Group, a major supplier of insecticidal compounds pyrethrins, a consolidated subsidiary.
Pyrethrins are insecticidal compounds extracted from the pyrethrum flower, which have the same basic chemical structure as synthetic pyrethroids. They are widely and commonly used in insecticides for household, vector control, pest control management and crop protection.
Since its establishment in 1996, the BRA Group has been producing pyrethrins in Tasmania, Australia. Through improvements made in the quality of pyrethrum seeds and the accumulation of know-how relating to the manufacturing of pyrethrins, the BRA Group has become a highly reliable supplier with the proven ability to provide consistently high-quality products.

Airgas to build new air separation unit in Mebane, US




Airgas USA LLC, an Air Liquide company said that it plans to build a new air separation unit (ASU) in Mebane, North Carolina.
The facility will increase Airgas’ production capabilities in North Carolina’s research triangle area while also strengthening its East Coast merchant gases network.
The new facility is expected to be on-stream in 2019 and will produce oxygen, nitrogen and argon for use in customer applications such as metal fabrication, blanketing and purging, combustion, chilling and freezing.
In addition, the ASU will produce medical grade oxygen to supply to hospitals, nursing homes and research laboratories as well as food and pharmaceutical grade nitrogen.
The ASU will support the region’s bulk gas market and enhance the company’s gas supply chain, to help ensure long-term reliability of supply for its merchant, packaged and on-site gas customers.
“Airgas continues to expand its gas production and distribution capabilities throughout US and looks forward to meeting the growing needs of gas customers in the thriving North Carolina market and throughout the region. We look forward to working closely with the Mebane community and the state of North Carolina to bring new opportunities and growth for many years to come,” said Pascal Vinet, CEO of Airgas and Air Liquide executive committee VP.

Rising incidence of cancer to drive the market




The global high potency active pharmaceutical ingredients (APIs) market was valued at $14.4 billion in 2016 and is expected to grow at a CAGR of 10.3 percent over the forecast period, according to a report by Grand View Research Inc.
Highly potent APIs are capable of targeting diseased cell selectively and more precisely than other compounds. Increasing incidence of cancer resulted in increasing R&D pertaining to anticancer drugs which thereby propelling the demand for HPAPIs over the forecast period.  
The rising number of biotech & pharmaceutical industry and increasing investments in R&D sector in developing economies such as Asia and Latin America regions are key factors expected to provide growth platform over the forecast period. 
Rising incidence of cancer is expected to drive the HPAPI market over the forecast period. Side effects related to chemotherapy such as it also affects non-cancerous cells hence targeted therapy approach is gaining popularity as it does not harm non-cancerous cells. This is attributed to the rising demand of HPAPI in the future.
The characteristics possessed by these anticancerous drugs such as minimum exposure of drug to the non-cancerous cell & effectiveness are the factor contributing to the market growth. In addition, HPAPI is also used as antibody-drug conjugates (ADCs). ADC are the most important & effective treatment in combination with monoclonal antibodies & biologically active drug for the cancer.
The drug’s use for cancer treatment is cytotoxic in nature and is harmful to the non-cancerous cells which cause extensive damage to patient’s health. Pharmaceutical industry is facing challenge related to harmful side effects of these drugs on normal cells of the body. While the use of a less effective drug is ineffective in cancer treatment hence the need for targeted therapy approach came into existence. HPAPI target cancer tissue effectively coupled with minimum exposure of drugs to healthy tissues
HPAPI are most commonly used in hormonal drugs which are used in the treatment of breast cancer. Glaucoma is the other most important application of HPAPI. Increasing demand for drugs for the treatment of glaucoma is expected to drive the market growth. The HPAPIs also found application in cardiovascular drugs, central nervous system drugs and musculoskeletal drugs.
Increasing demand for these drugs during the forecast period is anticipated to propel the market growth in coming years. In addition, rising usage of HPAPI in gynaecology & cosmetics are accounted for the further growth

Follow by Email